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ColistinAbstract Introduction: Ventilator-associated pneumonia [VAP] is associated with increased mor-
bidity and mortality especially when caused by extensive drug resistant [XDR] pathogens. Till now,
little is known regarding the exact pathogenesis of XDR Acinetobacter baumannii [XDR-AB] infec-
tion. The aim of the present study was to identify prevalence and risk factors for VAP caused by
XDR-AB in our intensive care unit, and to test the susceptibility pattern of tigecycline, carbapen-
ems, and Colistin among the isolates.
Methods: A prospective cohort study was conducted to enroll patients who developed VAP over
18-month period. All possible risk factors were documented as well as patient outcome. Suscepti-
bility testing for the isolates was performed using inhibitory concentrations [MICs] determined
by Epsilometer tests (E-tests) to Carbapenems, Tigecycline, and Colistin.
Results: Among 544 consecutive patients admitted to our ICU during 18 months, Forty-seven
patients developed VAP. The prevalence of XDR-AB was 63.8% (30 patients). No specific factor
was associated with increase of the risk of acquisition of AB-VAP in our cohort either by univariate
or by multivariate analysis. Carbapenems showed poor activity against all isolates [MIC range 10–
128 mg/L]. Tigecycline showed good activity against only 15 isolates [MIC range 0.25–2 mg/L].
Colistin demonstrated potent in vitro activity against all isolates of AB [MIC range 0.016–1 mg/L].
Conclusions: XDR AB-VAP is endemic in our ICU without a definite factor associated with
increased risk of infection. Given that almost half of the strains are also resistant to tigecycline, col-
istin appears to be an appropriate first-line antimicrobial drug in critically ill patients developing
VAP based on invitro results.
 2016 Publishing services by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
410 A. Hasanin et al.1. Introduction
Ventilator-associated pneumonia [VAP] is associated with pro-
longed mechanical ventilation, increased intensive care unit
[ICU] length of stay, and substantially increased mortality
[1]. Furthermore, the risk of mortality associated with VAP
increased when VAP is caused by one of multidrug-resistant
(MDR) pathogens [2].
Acinetobacter species [Acinetobacter spp.] is a non-
fermentative, aerobic, gram-negative coccobacilli, non-
lactose-fermenting and oxidase negative microorganism. Mul-
tiple mechanisms have been implicated in the resistance of
Acinetobacter spp. and it is considered one of the most virulent
MDR pathogens. Acinetobacter has been isolated in food and
inanimate objects and may colonize humans and survive on
dry or moist environment [3–5].
Carbapenems were considered for many years the mainstay
of therapy of VAP caused by Acinetobacter spp. [6]. However,
recent outbreaks of carbapenem-resistant Acinetobacter infec-
tion have raised the interest in colistin, an ‘old’ antibiotics
introduced in 1959 and was abandoned in the 1970s after
introduction of aminoglycosides [7,8]. However, the ability of
colistin to penetrate the lung tissue is a debatable issue and
moreover, it demonstrated dose-dependent neurotoxicity and
nephrotoxicity [9]. On the other hand, tigecycline is a newer
relatively safe broad spectrum tetracycline and displays inhibi-
tory activity against Acinetobacter spp. [10].
We previously reported the prevalence of extensive drug
resistant gram negative bacilli in our institution [11]; in this
study, we sought to conduct a prospective cohort study to
identify primarily the prevalence of VAP caused by extensive
drug resistant [XDR] Acinetobacter spp. and secondarily to
test the susceptibility pattern of tigecycline, carbapenems,
and colistin against VAP caused by Acinetobacter spp. as well
as the possible risk factors.
2. Methods
A cross sectional observational study was performed in Cairo
University hospitals surgical ICU admitting trauma and emer-
gency postoperative patients over 18-month period. All con-
secutive patients who were clinically suspected of having
developed VAP after 48 h of mechanical ventilation [MV] in
our ICU were included.
Patients were assumed to have VAP when new, persistent
infiltrate was seen on chest X-rays and at least two of the follow-
ing were observed: a body temperature below 36 C or above
38 C; a white blood cell count lower than 4000/mm3 or higher
than 11,000/mm3; and macroscopically purulent tracheal aspi-
rate [12]. Tracheal aspirate was classified as purulent or nonpu-
rulent after visual inspection by the clinical treatment team.
Once VAP was suspected, tracheal aspirate for quantitative
culture was obtained [Day 0], before antimicrobial treatment
was started (for patients not on current antimicrobial therapy).
Blood cultures were obtained for patients with suspected
bacteremia.
2.1. Bacteriological analysis
Tracheobronchial secretions were aseptically collected, follow-
ing specimen collection guidelines, after tracheal instillation of10 ml saline. The specimens were sent to the laboratory and
cultivated within 1 h of collection. A dilution of the tracheal
aspirate was prepared and inoculated with a calibrated loop
on chocolate, blood and MacConkey agar. After overnight
incubation in appropriate conditions, the plates were inter-
preted according to quantification of growth [13]. Qualitative
cultures were considered positive when the growth of 105
colony-forming units cfu/ml or more is observed.
All non-fermentative, oxidase-negative, catalase-positive,
strictly aerobic, motionless, Gram-negative coccobacilli were
considered belonging to Acinetobacter genus. [Phenotype iden-
tification was completed with API 20 NEsystem, Biome´rieux,
France].
Susceptibility testing was performed using inhibitory con-
centrations [MICs] determined by Epsilometer tests [E-tests;
AB.Biodisk, Sweden] for the following antibiotics: tigecycline,
colistin, and Imipenem.
Extensive drug resistance was defined as resistance to all
classes of antimicrobial agents except for one or two classes.
Modifications to the empirical therapy were based on the
results of tracheal aspirate cultures and blood cultures.
The severity of presenting illness was assessed by an Acute
Physiology and Chronic Health Evaluation II [APACHE II]
score calculated within 24 h of ICU admission. Other data col-
lection included smoking status; history of congestive heart
failure; history of malignancy; immunosuppression; albumin
level; use of H2 antagonists; proton pump inhibitor use; corti-
costeroid use; and the need for dialysis, cause of ICU admis-
sion, reoperation, use of blood product, central venous
catheterization, urinary tract catheterization duration of
mechanical ventilation, and duration of stay in the ICU before
VAP.
3. Statistical analysis
To assess risk factor status, two groups of patients were con-
sidered. AB-VAP: patients who developed VAP with Acineto-
bacter spp., and Non AB-VAP: patients who developed VAP
with other pathogens. All the pre-operative variables and
post-operative events were compared between the two groups
using univariate and multivariate analyses. Student’s t-test or
the Mann–Whitney U-test was used for quantitative data
and Pearson’s chi-square or Fisher’s exact test for categorical
data. Differences were considered statistically significant when
the p value is <0.2. Data were shown as mean ± SD or as
median and range or as percentages. All variables significant
in univariate analysis were analyzed by a multiple regression
logistic model. The forward stepwise logistic strategy was
applied, and variables were included in the model if the log
likelihood ratio chi-square test was significant. SPSS version
15.0 for Windows [SPSS, Inc., Chicago, IL, USA] was used
for statistical analyses.
4. Results
Among 544 consecutive patients admitted to our ICU during
18 months, total number of mechanically ventilated patients
was 243. Forty-seven patients [19.3%] developed VAP. The
prevalence of Acinetobacter spp. was 30 [63.8%].
Demographic and baseline data were comparable among
both groups [Table 1]. There is no specific factor associated
Table 1 Demographic data. Data are described as mean
± SD, median (quartiles).
AB-VAP patients
(n= 30)
Non-AB-VAP
patients (17)
P
value
Age (years) 39 ± 22 43 ± 20 0.5
Gender
(male/female)
19/11 12/5 0.7
APACHE II 18(15–22) 17(15–22) 0.8
SOFA on admission 6(3–8) 5(2–8) 0.5
Table 2 Risk factors for acquisition of VAP. Data are
presented as mean ± standard deviation and number
(frequency).
AB-VAP
patients
(n= 30)
Non-AB-VAP
patients
(n= 17)
P
value
Diabetes 6(20%) 5(29.4%) 0.4
Blood transfusion
{number of patients (%)}
10(33.3%) 5(29.4%) 0.7
Sepsis 7(23.3%) 7(41.2%) 0.2
Serum Albumin
(gm/dl)
2.5(2.2–3.1) 2.3(2.3–2.6) 0.6
Previous antimicrobial
therapy
12(40.0%) 8(47.1%) 0.63
Previous mechanical
ventilation
6(20.7%) 5(29.4%) 0.5
Duration of ventilation
before infection
6 ± 4 4 ± 4 0.1
TPN 3(10%) 1(5.9%) 0.3
H2 blockers 26(86.7%) 15(88.2%) 0.87
Proton pump inhibitors 4(13.3%) 3(17.6%) 1.0
Steroids 15(50%) 7(41%) 0.6
Patients with
previously inserted
central line
27(90%) 13(76.5%) 0.3
Previous surgery 11(36.7%) 9(52.9%) 0.27
Patients with history of
repeated operation
7(23.3%) 4(23.5%) 0.9
Hemodialysis 6(20%) 1(5.9%) 0.24
Table 3 Multivariate analysis factor predicting AB-VAP.
Odds ratio 95% CI P value
APACHE II <20 1 (0.2–4) 0.09
>20 1.08 (0.2–4) 0.09
Dialysis Yes 1 (0.6–3.7) 0.4
No 0.8 (0.6–3.7) 0.4
Diabetes Yes 1 (0.4–12) 0.4
No 2.1 (0.4–12) 0.4
Transfusion Yes 1 (0.2–5) 0.9
No 0.9 (0.2–5) 0.9
TPN Yes 1 (0.8–14) 0.9
No 1.5 (0.8–14) 0.9
Reoperation Yes 1 (0.75–5) 0.76
No 1.2 (0.75–5) 0.76
Table 4 Patients outcome. Data are presented as median
(IQR), and number (frequency).
AB-VAP patients
(n= 30)
Non-AB-VAP
patients (n= 17)
P
value
Ventilation
days
7(6–11) 11(7–16) 0.2
Length of
ICU stay
15(11–34) 20(15–40) 0.2
Mortality 16(53.3%) 9(52.9%) 0.75
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cohort either by univariate or by multivariate analysis [Tables
2 and 3]. Length of hospital stay was 9 ± 4 days in the AB-
VAP versus 7 ± 4 days in the non-AB-VAP group [P= 0.1].
Overall the in-hospital mortality was 25 [53.2%]. Moreover,
the incidence of mortality for patients in AB-VAP group was
16 [53.3%] and this was not different from mortality in the
non-AB-VAP group of 9 [52.9%] [p= 0.75] [Table 4].
Carbapenems showed poor activity against all Acinetobac-
ter spp. [MIC range 10–128 mg/L]. Tigecycline showed good
activity against 15 isolates [MIC range 0.25–2 mg/L], moderate
activity against 10 isolates [MIC range 2.5–4 mg/L], and poor
activity against 5 isolates of Acinetobacter spp. [MIC range
10–12 mg/L].
Colistin demonstrated potent in vitro activity against all
isolates of Acinetobacter spp. [MIC range 0.016–1 mg/L].5. Discussion
The main finding of the study described herein, was that the
prevalence of ventilator associated pneumonia induced by
XDR-resistance Acinetobacter spp. was high in our critical
care unit approaching 2/3 of all isolated species.
Consistent with our finding, several authors have shown
that Acinetobacter spp. is the most prevalent multidrug resis-
tant pathogens in patients with VAP [14–17]. A previous study
in our unit addressed the prevalence of extensive drug resistant
gram negative bacilli; however, the antimicrobial resistance to
carbapenems in Acinetobacter spp. was lower than that in our
findings and this is most probably due to increased use of car-
bapenems in our unit last year [11].
Previous use of antibiotics, central venous catheter, urinary
catheter, hemodialysis, nasogastric tube, trauma, malignancy,
previous septic shock, and the duration of hospital stay was
previously reported to be independent risk factors for Acineto-
bacter infection [18–20]. In the present study we did not find
any factor associated with increased risk of VAP caused by
Acinetobacter spp. Furthermore, VAP caused by Acinetobacter
was not associated with increased risk of mortality. One way to
explain this result was that, most of patients developed VAP in
our study were infected with MDR pathogens and we believe
that most of the aforementioned factors are independent risks
for multidrug resistant in general and not for specific
pathogens.
In the study described herein, 100% of isolated Acinetobac-
ter spp. were resistant to carbapenems. In line with our results,
several studies have reported that carbapenem resistance of
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ranged from 55% to 81% [21,22].
On the other hand, colistin demonstrated potent in vitro
activity against all Acinetobacter isolates in our cohort. Similar
to this finding, several authors have shown that colistin main-
tained significant in vitro activity against Acinetobacter spp.
and the colistin-resistant Acinetobacter isolates were recovered
from patients who had been pre treated with Colistin [23–25].
Colistin was not available at our institution till few months
before the beginning of our study; even after it was available
it was not prescribed except for patients with cultures suscep-
tible only for it. Thus, colistin in vitro activity is well preserved.
In the current study, we can consider that the activity of
tigecycline was inadequate against XDR-Acinetobacter spp.
given that, only 50% of the isolated carbapenem resistant
Acinetobacter spp. showed good susceptibility to this agent.
Consistent with our finding, inadequate activity of tigecycline
against carbapenem-resistant Acinetobacter spp. has been
demonstrated in several studies [26,27]. However, other studies
reported adequate activity which is defined as 90% susceptibil-
ity of the total number of Acinetobacter isolates to tigecycline
[28,29]. Tigecycline is rarely used in our hospital that makes
the fact of having resistant strains a matter of interest. The
mechanism of carbapenem resistance is quite different from
resistance to tigecycline making the concept of cross resistance
between the two agents unlikely to occur. A possible explana-
tion is that clinical strains of Acinetobacter spp. under study
possess several mechanisms (possibly interrelated) that enable
them to develop resistance to various antimicrobial drugs.
Several debatable issues have been recently raised regarding
the use of tigecycline for treatment of Acinetobacter spp. First
of all, there is no universally accepted interpretation of MIC
breakpoint. The Food and Drug Administration [FDA]-
approved MIC breakpoints for susceptibility and resistance
are 62 and P8 mg/L, respectively, whereas the corre-
sponding European Committee on Antimicrobial Susceptibil-
ity Testing EUCAST breakpoints are 61 and P2 mg/L
respectively [30]. Secondly, tigecycline has been approved for
the treatment of complicated intra-abdominal infections, com-
plicated skin and soft tissue infections, and its role in VAP is
questionable and more recently, the FDA determined that tige-
cycline resulted in increased mortality risk, especially in
hospital-acquired pneumonia, compared with other antibiotics
[31,32].
The increasing pattern of antimicrobial resistance among
our patients, as well as patients in other parts of the world,
including tigecycline is an alarming threat that made colistin
to be the last effective drug in VAP. This increased pattern
of antimicrobial resistance needs aggressive implementation
of infection control measures as well as antibiotic stewardship
to avoid reaching a pre-antibiotic Era.
6. Conclusion
Our study has shown that extensive drug resistant Acinetobac-
ter spp. VAP is endemic in our ICU without a definite factor
associated with increased risk of infection. Given that almost
half of the strains are also resistant to tigecycline, colistin
appears to be an appropriate first-line antimicrobial drug in
critically ill patients developing VAP. Our results are basedonly on invitro findings and need to be confirmed in the clini-
cal setting in future studies.
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